Literature DB >> 8412748

Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency.

S W Brusilow1, J Finkelstien.   

Abstract

We evaluated the hypothesis that sodium phenylbutyrate-induced phenylacetylglutamine biosynthesis in a man with partial ornithine transcarbamylase (OTC) deficiency has a dual effect; it provides an additional vehicle for waste nitrogen excretion, and in the process it suppresses the patient's residual urea N synthesis, which then may be available for N homeostasis if the need arises. A 38-year-old man was studied over three periods. Period I was a control period during which he received a fixed caloric and N intake plus L-citrulline. Phenylbutyrate was added in period II and was maintained during period III, during which his N intake was increased. Plasma levels of ammonium and glutamine and net urea N synthesis were measured in each period; phenylacetylglutamine N synthesis was measured in periods II and III. These studies demonstrated that phenylbutyrate administration led to a 73% decrease in net de novo urea N synthesis during period II, which subsequently increased threefold in period III in response to the increased N intake. Phenylacetylglutamine N synthesis was 2.27 g/d, similar to his estimated maximum net urea N synthesis of 2.65 g/d. During periods II and III, his plasma levels of ammonium and glutamine improved as compared with period I when they were abnormally high. We conclude that sodium phenylbutyrate treatment of patients with urea cycle disorders who have significant residual enzyme activity results in both an improvement in waste N excretion and improved N homeostasis as a result of the generation of a reserve urea N synthetic capacity. This therapeutic approach may be useful in other nitrogen accumulation decreases, eg, portal-systemic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8412748     DOI: 10.1016/0026-0495(93)90135-b

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  11 in total

1.  Inhibitory effect of 1-O (2 methoxy) hexadecyl glycerol and phenylbutyrate on the malignant properties of human prostate cancer cells.

Authors:  S Reynolds; H Cederberg; S Chakrabarty
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  "Fold Here"-Chemical Correctors in the Treatment of Epilepsy.

Authors:  Adam L Hartman
Journal:  Epilepsy Curr       Date:  2015 Nov-Dec       Impact factor: 7.500

3.  Nitric oxide and L-arginine metabolism in a devascularized porcine model of acute liver failure.

Authors:  Vikram Sharma; Gabriella A M Ten Have; Lars Ytrebo; Sambit Sen; Christopher F Rose; R Neil Dalton; Charles Turner; Arthur Revhaug; Hans M H van-Eijk; Nicolaas E P Deutz; Rajiv Jalan; Rajeshwar P Mookerjee; Nathan A Davies
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-15       Impact factor: 4.052

4.  Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.

Authors:  Uta Lichter-Konecki; G A Diaz; J L Merritt; A Feigenbaum; C Jomphe; J F Marier; M Beliveau; J Mauney; K Dickinson; A Martinez; M Mokhtarani; B Scharschmidt; W Rhead
Journal:  Mol Genet Metab       Date:  2011-05-05       Impact factor: 4.797

5.  Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.

Authors:  Brendan Lee; William Rhead; George A Diaz; Bruce F Scharschmidt; Asad Mian; Oleg Shchelochkov; J F Marier; Martin Beliveau; Joseph Mauney; Klara Dickinson; Antonia Martinez; Sharron Gargosky; Masoud Mokhtarani; Susan A Berry
Journal:  Mol Genet Metab       Date:  2010-03-23       Impact factor: 4.797

6.  Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.

Authors:  Wendy Smith; George A Diaz; Uta Lichter-Konecki; Susan A Berry; Cary O Harding; Shawn E McCandless; Cindy LeMons; Joe Mauney; Klara Dickinson; Dion F Coakley; Tristen Moors; Masoud Mokhtarani; Bruce F Scharschmidt; Brendan Lee
Journal:  J Pediatr       Date:  2013-01-13       Impact factor: 4.406

7.  Phenylbutyrate induces antimicrobial peptide expression.

Authors:  Jonas Steinmann; Skarphédinn Halldórsson; Birgitta Agerberth; Gudmundur H Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

8.  The plasma flux and oxidation rate of ornithine adaptively decline with restricted arginine intake.

Authors:  L Castillo; M Sánchez; T E Chapman; A Ajami; J F Burke; V R Young
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

9.  Functional rescue of mutant ABCA1 proteins by sodium 4-phenylbutyrate.

Authors:  Brie Sorrenson; Rachel J Suetani; Michael J A Williams; Vivienne M Bickley; Peter M George; Gregory T Jones; Sally P A McCormick
Journal:  J Lipid Res       Date:  2012-10-20       Impact factor: 5.922

10.  Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.

Authors:  M Mokhtarani; G A Diaz; W Rhead; U Lichter-Konecki; J Bartley; A Feigenbaum; N Longo; W Berquist; S A Berry; R Gallagher; D Bartholomew; C O Harding; M S Korson; S E McCandless; W Smith; J Vockley; S Bart; D Kronn; R Zori; S Cederbaum; N Dorrani; J L Merritt; Sandesh Sreenath-Nagamani; M Summar; C Lemons; K Dickinson; D F Coakley; T L Moors; B Lee; B F Scharschmidt
Journal:  Mol Genet Metab       Date:  2012-08-18       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.